165 related articles for article (PubMed ID: 8002644)
1. Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans.
Pershing LK; Lambert L; Wright ED; Shah VP; Williams RL
Arch Dermatol; 1994 Jun; 130(6):740-7. PubMed ID: 8002644
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.
Pershing LK; Silver BS; Krueger GG; Shah VP; Skelley JP
Pharm Res; 1992 Jan; 9(1):45-51. PubMed ID: 1589409
[TBL] [Abstract][Full Text] [Related]
3. Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo.
Pershing LK; Corlett JL; Lambert LD; Poncelet CE
J Invest Dermatol; 1994 May; 102(5):734-9. PubMed ID: 8176255
[TBL] [Abstract][Full Text] [Related]
4. New approaches to assess topical corticosteroid bioequivalence: pharmacokinetic evaluation.
Pershing LK
Int J Dermatol; 1992 Oct; 31 Suppl 1():14-20. PubMed ID: 1428461
[TBL] [Abstract][Full Text] [Related]
5. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.
Schwarb FP; Smith EW; Haigh JM; Surber C
Eur J Pharm Biopharm; 1999 May; 47(3):261-7. PubMed ID: 10382110
[TBL] [Abstract][Full Text] [Related]
6. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
7. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.
Demana PH; Smith EW; Walker RB; Haigh JM; Kanfer I
Pharm Res; 1997 Mar; 14(3):303-8. PubMed ID: 9098871
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
Wiedersberg S; Naik A; Leopold CS; Guy RH
Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
[TBL] [Abstract][Full Text] [Related]
10. Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians.
Fleischer AB; Feldman SR
Clin Ther; 1999 Oct; 21(10):1725-31. PubMed ID: 10566568
[TBL] [Abstract][Full Text] [Related]
11. Enhanced topical delivery and ex vivo anti-inflammatory activity from a betamethasone dipropionate formulation containing fish oil.
Zulfakar MH; Abdelouahab N; Heard CM
Inflamm Res; 2010 Jan; 59(1):23-30. PubMed ID: 19644736
[TBL] [Abstract][Full Text] [Related]
12. In vitro penetration through the skin layers of topically applied glucocorticoids.
Carrer V; Alonso C; Oliver MA; Coderch L
Drug Test Anal; 2018 Oct; 10(10):1528-1535. PubMed ID: 29788546
[TBL] [Abstract][Full Text] [Related]
13. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
[TBL] [Abstract][Full Text] [Related]
14. Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment.
Sequira J; Berardi M; Chan TM; Letarte J; Malchow R; Pramanick B; Wolkoff HN
Clin Ther; 1991; 13(6):687-94. PubMed ID: 1790543
[TBL] [Abstract][Full Text] [Related]
15. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.
Schwarb FP; Imanidis G; Smith EW; Haigh JM; Surber C
Pharm Res; 1999 Jun; 16(6):909-15. PubMed ID: 10397613
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of betamethasone dipropionate when combined with calcipotriol.
Traulsen J
Int J Dermatol; 2004 Aug; 43(8):611-7. PubMed ID: 15304191
[TBL] [Abstract][Full Text] [Related]
17. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
18. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
Hashim PW; Nia JK; Terrano D; Goldenberg G; Kircik LH
J Drugs Dermatol; 2017 Aug; 16(8):747-752. PubMed ID: 28809989
[TBL] [Abstract][Full Text] [Related]
19. Intermittent topical treatment of psoriasis with betamethasone dipropionate 0.05 percent cream.
van Dijk E; Bakkers EJ; Go MJ; Montnor LP; Roessel FE; van der Wateren AR; Wuite J
Cutis; 1983 Sep; 32(3):284-5, 287. PubMed ID: 6354613
[TBL] [Abstract][Full Text] [Related]
20. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis.
Fowler JF; Hebert AA; Sugarman J
J Drugs Dermatol; 2016 Feb; 15(2):154-62. PubMed ID: 26885782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
